MA-HOLOGIC,-INC.
Hologic, Inc. (Nasdaq: HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere’s respiratory viral season. Both assays detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV).
The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is a high-performance cartridge-based assay that runs on the fully automated high-throughput Panther Fusion system. The test uses nasopharyngeal swab samples.
The Novodiag RESP-4 assay runs on the Novodiag system, the fully automated molecular diagnostic solution that delivers on-demand testing for infectious disease and antimicrobial resistance. This test also uses nasopharyngeal swab samples and includes an embedded cellularity control to ensure that the sample was correctly taken.
Both products are compliant with the European In Vitro Diagnostic Medical Device Directive (IVDD) 98/79/EC, and transition provisions for such devices included in the IVD Regulation (EU) 2017/746.
“As we move into the next phase of COVID, it is important that we evolve our assays to support our customers with tests that enable them to differentiate between the multiple respiratory pathogens as easily as possible. The ability to accurately differentiate between respiratory viruses with similar symptoms is essential if physicians are to ensure optimized care for each patient,” said Jan Verstreken, Group President International. “Together, these two assays further build our international offering of molecular diagnostic scalable solutions that meet the growing needs of a broad range of customers, from single-patient rapid testing to population-level screening.”
He continued, “The RESP-4 assay, developed and manufactured in Espoo, Finland is the first new Novodiag assay to be launched since Hologic’s acquisition of Mobidiag in June 2021. The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay was developed and will be manufactured at our facility in San Diego, CA. It adds to our quickly growing menu of Panther Fusion assays, including the Panther Fusion EBV and BKV assays designed and manufactured at our recently acquired facility in Liège, Belgium.”
The launch of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay adds to the respiratory portfolio for the Panther Fusion system, which currently includes the Panther Fusion Flu A/B/RSV assay, the Panther Fusion Paraflu (Parainfluenza 1/2/3/4) assay, the Panther Fusion AdV/hMPV/RV (adenovirus/human metapneumovirus/rhinovirus) and the Panther Fusion Bordetella assay.
The launch of the Novodiag RESP-4 assay further expands the Novodiag assay menu, which currently includes diagnostic assays for gastrointestinal infections, hospital acquired infections, antimicrobial resistance and respiratory infections.
For more information visit www.hologic.com .
About the Panther and Panther Fusion Systems
The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform that can be used in low-, medium- or high-throughput laboratories. With a small footprint, adaptable workflow options and consolidated testing menu, it combines women’s health, sexually transmitted infection and viral load testing, which can all be done simultaneously. The Panther Fusion system provides an expanded in vitro diagnostics menu, as well as Open AccessTM functionality to run laboratory developed tests.
About the Novodiag System
The Novodiag system combines real-time PCR and microarray capabilities that enable multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. It delivers clinically relevant results in central labs or tertiary settings and its rapid ‘sample-in, result-out’ system allows for the fully automated detection of novel coronavirus in approximately one hour. It can be used as the main molecular platform for emergency, decentralised, and out-of-hours testing, or in association with the Panther® System.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Forward Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance that these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, The Science of Sure, Mobidiag, Novodiag, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. in the United States and/or other countries.
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005201/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing22.1.2026 12:00:00 CET | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K. As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with Zhonghua to complete the required audit and t
Sisvel Launches Wi-Fi Multimode Patent Pool22.1.2026 12:00:00 CET | Press release
Ten patent owners establish licensing solution covering Wi-Fi 6 and Wi-Fi 7 standards Sisvel has launched a groundbreaking Wi-Fi Multimode patent pool offering access to standard essential patents owned by 10 Wi-Fi 6 and Wi-Fi 7 technology leaders. As the successor to Sisvel’s highly successful Wi-Fi 6 patent pool – which, over a three-year period, closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP – the new programme offers an efficient way to access essential Wi-Fi rights for years to come. The 10 founding patent owners in the Wi-Fi Multimode programme are Huawei, KPN, Mitsubishi Electric, Orange, Panasonic, Philips, Aegis 11 SA (a Sisvel affiliate), SK Telecom, Wilus and ZTE. In addition, Sony Group Corporation has taken a licence under the Wi-Fi Multimode programme. This early agreement with a sophisticated and globally recognised Wi-Fi leader and implementer underlines the pool’s strong value proposition and the efforts made by Sisvel to engage with
Otto Group Enables AI-driven Intelligent Robot Coordination With the Digital Twin Developed by Roboverse Reply22.1.2026 11:52:00 CET | Press release
Reply [EXM, STAR: REY] is supporting the global retailer Otto Group in implementing a central, AI-driven virtual control system for intelligent robotic orchestration. Developed as part of a strategic collaboration between Otto Group, Reply, and NVIDIA, the "Robotic Coordination Layer" enables the training, simulation, and orchestration of autonomous mobile robots and stationary systems, accelerating delivery times and enhancing service levels This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122331989/en/ This initiative with the Otto Group and NVIDIA underscores Roboverse Reply’s role as an implementation partner for AI-powered robotics and Physical AI in logistics. At the centre is a high-fidelity digital twin, serving as a precise replica of the warehouse environment and accurately representing the positions, movements, and interactions of all robotic systems. Developed thanks to Roboverse Reply’s expertise in robotic int
Bureau Veritas Named Accredited EcoVadis Consulting Partner22.1.2026 11:30:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), has been named as an Accredited Consulting Partner by EcoVadis, the global standard for resilient, sustainable supply chains. Accredited Consulting Partners are formally equipped to help businesses complete sustainability assessments, review scores, and improve Environment, Labor and Human Rights, Ethics, and Sustainable Procurement practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122971773/en/ Accredited Consulting Partners are carefully selected based on their experience and expertise and must complete rigorous training on EcoVadis’ methodology and assessment process through the EcoVadis Academy. To qualify, partners must demonstrate a deep understanding of local environmental, ethical and human rights regulations and issues, and have completed the EcoVadis assessment for their own business. “Becoming an EcoVadis Accredite
Nordic Firms Seek Sovereign Clouds for Compliant Modernization22.1.2026 10:00:00 CET | Press release
Enterprises reshape cloud strategies around data sovereignty, sustainability requirements and AI-native operations, ISG Provider Lens® report says The multi public cloud services market in the Nordics has entered a defining phase as enterprises shift from selective use of the cloud to comprehensive, compliance-driven and AI-native multicloud operating models, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2025 ISG Provider Lens® Multi Public Cloud Services report for the Nordics finds that cloud adoption across the region has moved beyond basic workload migration as companies embrace sovereign cloud models that guarantee jurisdictional control and encryption frameworks. This change reflects the impact of tightening EU regulatory frameworks that require data residency, transparency and responsible AI adoption in regulated industries and the public sector. As a result, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom